Daiichi Sankyo To Increase ActHIB Vaccine Supplies To End Backlog
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo said it plans to expand its inventory of a vaccine against hemophilus influenza type B in infants. France's Sanofi Pasteur produces the drug and Daiichi Sankyo has licensing rights in Japan